Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 7,089 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Breast Cancer Clear all

Conditions: Breast Cancer
Interventions: Adriamycin and Cytoxan (AC), ABI-007, Taxol, Bevacizumab, pegfilgrastim; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 27
States / cities: Birmingham, Alabama • Sedona, Arizona • Denver, Colorado + 23 more

Conditions: Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, Advanced Cervical Carcinoma, Advanced Endometrial Carcinoma, Advanced Esophageal Carcinoma, Advanced Gastric Carcinoma, Advanced Head and Neck Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Penile Carcinoma, Advanced Pleural Malignant Mesothelioma, Advanced Urothelial Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Intrahepatic Bile Duct Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Penile Cancer AJCC v8, Stage III Pleural Diffuse Malignant Mesothelioma AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Bile Duct Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Pleural Diffuse Malignant Mesothelioma AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Urothelial Carcinoma
Interventions: Cisplatin, Elimusertib, Gemcitabine Hydrochloride; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Sacramento, California • Bethesda, Maryland • New York, New York + 3 more

Conditions: Breast Cancer, Breast Cyst, Microcalcification
Interventions: Imaging; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 252 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2037
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HER2 Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer
Interventions: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer
Interventions: Melatonin, Placebo, Questionnaire; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 40 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neoplasms, Breast
Interventions: lapatinib + capecitabine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 159
States / cities: Huntsville, Alabama • Anchorage, Alaska • Glendale, Arizona + 135 more

Conditions: ER+ Breast Cancer
Interventions: Elacestrant; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more

Conditions: Breast Cancer
Interventions: Denosumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions: Questionnaire Administration, Tonation Breathing Technique; Other · Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer
Interventions: Rucaparib, Radiotherapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 8
States / cities: Norwalk, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Breast Cancer
Interventions: Bexa and focus ultrasound; Device
Lead sponsor: Sure, Inc.; Industry
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Abilene, Texas

Conditions: Breast Cancer, Triple Negative Breast Cancer
Interventions: Talazoparib, Atezolizumab, Radiation; Drug · Radiation
Lead sponsor: Mylin A. Torres, MD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Birmingham, Alabama • Atlanta, Georgia

Conditions: Breast Cancer
Interventions: Radiation Therapy (RT), Capecitabine, Trastuzumab, Paclitaxel; Radiation · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Breast Cancer
Interventions: biomarker study; Other
Lead sponsor: Side-Out Foundation; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Miami, Florida + 4 more

Conditions: Breast Cancer, Cervical Cancer, Colorectal Cancer
Interventions: educational intervention, study of socioeconomic and demographic variables; Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 40 Years to 69 Years · Female only
Enrollment: 2,729 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2001
U.S. locations: 2
States / cities: Lebanon, New Hampshire • New York, New York

Conditions: Cancer, Severe Major Depression, Schizophrenia, Bipolar Disorder, Lung Cancer, Breast Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Genitourinary Cancer
Interventions: Virtual Cancer and Mental Health Tumor Board; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Danvers, Massachusetts

Conditions: Cancer
Interventions: cyclophosphamide, Cryoablation; Drug · Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Pregnancy
Interventions: Trastuzumab, Pertuzumab, Ado-Trastuzumab Emtansine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Node Positive Breast Cancer
Interventions: Radiation therapy groups; Radiation
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 95 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Breast Cancer
Interventions: Diffuse Optical Spectroscopy Imaging; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 2
States / cities: Irvine, California • Orange, California

Conditions: Low-Risk, Early Stage Breast Cancer
Interventions: Cryoablation; Device
Lead sponsor: IceCure Medical Ltd.; Industry
Eligibility: 70 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 3
States / cities: Glendale, California • Portland, Oregon • Germantown, Tennessee

Conditions: Breast Cancer
Interventions: Arm Exercises; Procedure
Lead sponsor: University of New Mexico; Other
Eligibility: Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Pancreatic Cancer
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation, Duffy Blood Group, Chemokine Receptor Gene C.-67T>C
Interventions: Dexamethasone, Bortezomib, LENALIDOMIDE, Daratumumab, Carboplatin, Paclitaxel, Pembrolizumab, Cyclophosphamide, Doxorubicin; Drug
Lead sponsor: Andrew Hantel, MD; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts • Cincinnati, Ohio

Search by objective public record fields.

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

Advanced Ultrasound Signal Processing of Suspicious Breast Images

Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

Melatonin Postoperative Sleep Study in Breast Cancer Patients

EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

Circulating Tumor DNA

Denosumab for Breast Cancer With Bone Mets

Tonation Breathing Technique Method to Ease Aromatase Inhibitor-induced Joint and/or Muscle Pain

A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy

Evaluation of the Bexa Breast Examination

A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer

Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics

Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer

A Telephone-Based Prevention Care Manager in Increasing Screening Rates for Breast Cancer, Cervical Cancer, and Colorectal Cancer in Minority and Low-Income Women

Adapting the Tumor Board Model for Mental Illness and Cancer

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine

Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation

Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy

Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)

Arm Function and Quality of Life Following Mastectomy.

Validation of a Mouse Model of Pancreatic Carcinogenesis

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype